Literature DB >> 15886152

Why are pharmaceutical companies gradually abandoning vaccines?

Paul A Offit1.   

Abstract

During the past fifty years, the number of pharmaceutical companies making vaccines has decreased dramatically, and those that still make vaccines have reduced resources to make new ones. Pharmaceutical companies are gradually abandoning vaccines because the research, development, testing, and manufacture of vaccines are expensive and because the market to sell vaccines is much smaller than the market for other drug products. Congressional action could assure both a steady supply of existing vaccines and the promise of vaccines for the future.

Mesh:

Substances:

Year:  2005        PMID: 15886152     DOI: 10.1377/hlthaff.24.3.622

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  13 in total

1.  Can patent duration hinder medical innovation.

Authors:  Patrick Leoni; Alvaro Sandroni
Journal:  Int J Health Econ Manag       Date:  2016-09-02

2.  Childhood immunization policies and the prevention of communicable disease.

Authors:  James H Conway; Tiffany Green
Journal:  Pediatr Ann       Date:  2011-03       Impact factor: 1.132

Review 3.  Moving beyond Titers.

Authors:  Benjamin D Brooks; Alexander Beland; Gabriel Aguero; Nicholas Taylor; Francina D Towne
Journal:  Vaccines (Basel)       Date:  2022-04-26

Review 4.  Malaria vaccines: looking back and lessons learnt.

Authors:  Veronique Lorenz; Panagiotis Karanis
Journal:  Asian Pac J Trop Biomed       Date:  2011-01

5.  Access to influenza vaccine in East Harlem and the Bronx during a national vaccine shortage.

Authors:  Danielle C Ompad; Sandro Galea; Shannon Blaney; Micaela H Coady; Sarah Sisco; Kathryn Glidden; David Vlahov
Journal:  J Community Health       Date:  2007-06

Review 6.  Malaria vaccine development and how external forces shape it: an overview.

Authors:  Veronique Lorenz; Gabriele Karanis; Panagiotis Karanis
Journal:  Int J Environ Res Public Health       Date:  2014-06-30       Impact factor: 3.390

Review 7.  Comparison of regulatory framework of clinical trial with genetically modified organism-containing vaccines in the Europe, Australia, and Switzerland.

Authors:  Jobin Jose; Swathi Pai
Journal:  Clin Exp Vaccine Res       Date:  2021-05-31

Review 8.  The current state of drug discovery and a potential role for NMR metabolomics.

Authors:  Robert Powers
Journal:  J Med Chem       Date:  2014-03-03       Impact factor: 7.446

Review 9.  Synthetic biology for bioengineering virus-like particle vaccines.

Authors:  Hayley K Charlton Hume; João Vidigal; Manuel J T Carrondo; Anton P J Middelberg; António Roldão; Linda H L Lua
Journal:  Biotechnol Bioeng       Date:  2018-12-31       Impact factor: 4.530

Review 10.  Vaccine supply, demand, and policy: a primer.

Authors:  Jagannath M Muzumdar; Richard R Cline
Journal:  J Am Pharm Assoc (2003)       Date:  2009 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.